Biogen Update July 26, 2019
This is not a recommendation or proposal to do anything. The data written in this article is not guarranteed. It is my private personal opinion. I`m not independing as I own a position of Biogen shares.
My personal knowledge about pharmacy is very limited. It is difficult for me to evaluate medicine in terms of efficacy, market position, potential pricing and potential revenues. Hence I`m perhaps not the best analyst for pharmaceutical companies.
Biogen, Symbol: BIIB, is one of the largest biotech companies with revenues of about 14bn$ (estimate 2019) and a market capitalization of nearly 46bn$ (share price 240$). The main businesses are the MS business with revenues of 9.1 bn$ incl. royalties (2018) and the Spinaraza Spinal muscular atrophy business with revenues of 1.7 bn$. It adds a smaller less profitable biosimilar business.
Chances & Risks
The actual PE of 8! (240$ share price) and the guidance for 2019 seems very inexpensive.
Existing pharmaceutics loosing sooner or later their patent protection or are replaced by better ones. That means the revenues from the existing portfolio are declining sooner or later. The main question is if there are enough new products in the pipeline to replace the declining revenues from existing products.
Acc. to BIIB presentation the company has 6 products in phase III, 13 products in phase II and 8 in phase I. As a rule of thumb...For every 10 that head into clinical trials with high hopes, one will get to market. It is the question how many of these products are getting into the market and how well these products perform. But anyhow even if the lost revenues should not become replaced completly....
It seems as BIIB buys products and company`s with new developments in a later stage to increase its pipeline (see news June 7, 2019).
A reason to buy BIIB is the high return to the shareholders. There is 1 bn$ left from the 2018 share buyback program and another 5 bn$ share buy back program is decided for 2019. 6bn $ share buy back means buying about 27 mio. share or >10% of the outstanding shares.
Q2/2019 Data: Revenue 3.62 bn$, Net income 1494 mio. $, EPS 7.85$/share
Q1/2019 Data: Revenue 3.49 bn$ Net Income 1409 mio. $, EPS 7.15$/share,
Diluted eps (2018): $21.58, Guidance 2019: $29.6 to $30.4 share price 240 $ -> PE 8!
The guidance for 2019 seems conservative!
Number of Shares: 220,508,784 Outstanding 184.4 mio. Remainder treasury Shares. That is at a share price of 240$ a market capitalization of 45.6 bn$.
The core MS business is slowly declining.
(in millions) 2Q 2019 1Q 2019 1Q 2018 4Q 2018
Tecfidera 1150 999 987 1,110
Avonex 438 397 451 481
Plegridy 117 104 100 116
Tysabri 475 460 462 464
Fampyra 24 23 24 23
Total MS 2204 1,983 2,024 2,194
Spinraza 488 518 364 470
Biosimilars 184 175 156
Q2 /2019...Cost of sales 476 mio.$ 13%!, R&D 485 mio. $ 13%!,
Acc. to an agreement with Ionis, BIIB makes royalty payments to Ionis on annual worldwide net sales of SPINRAZA using a tiered royalty rate between 11% and 15%, which are recognized in cost of sales within the consolidated statements of income. Royalty cost of sales related to sales of SPINRAZA for the years ended December 31, 2018, 2017 and 2016, it totaled $238.0 million, $112.4 million and $0.5 million, respectively.
June 07,2019 BIIB announced that it bought Nightstar Therapeutics (NST), a clinical-stage gene therapy company, focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. As a result Biogen got ded two mid- to late-stage clinical assets, as well as preclinical program, in ophthalmology. BIIB paid $800 million(5).
Shareholders from market screener (4)
PRIMECAP Management Co. 7.38%
The Vanguard Group, Inc. 7.20%
BlackRock Fund Advisors 5.40%
ClearBridge Investments LLC 4.39%
SSgA Funds Management, Inc. 4.39%
Wellington Management Co. LLP 2.75%
Fidelity Management & Research Co. 2.04%
AllianceBernstein LP 1.55%
AQR Capital Management LLC 1.50%
Northern Trust Investments, Inc. 1.38%
The big asset managers hold an important share of Biogen
Biogen investor relations
(6) 2019/07/26 https://seekingalpha.com/filing/4570750
(4) 2019/05/21 https://www.marketscreener.com/BIOGEN-4853/company/
(1) 2019/01/29 https://seekingalpha.com/article/4236192-biogen-inc-2018-q4-results-earnings-call-slides?app=1&dr=1